Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112 in relapsed or refractory multiple myeloma
NCT07312188Phase 2Recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jul 2025
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of F182112 in multiple myeloma (MM), sponsored by Shandong New Time Pharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07312188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312188.